Arcturus Therapeutics Holdings (ARCT) Non-Current Deffered Revenue (2018 - 2025)
Historic Non-Current Deffered Revenue for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $4.2 million.
- Arcturus Therapeutics Holdings' Non-Current Deffered Revenue fell 6836.11% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 6836.11%. This contributed to the annual value of $12.6 million for FY2024, which is 7034.07% down from last year.
- Latest data reveals that Arcturus Therapeutics Holdings reported Non-Current Deffered Revenue of $4.2 million as of Q3 2025, which was down 6836.11% from $8.8 million recorded in Q2 2025.
- Arcturus Therapeutics Holdings' Non-Current Deffered Revenue's 5-year high stood at $42.5 million during Q4 2023, with a 5-year trough of $4.2 million in Q3 2025.
- Its 5-year average for Non-Current Deffered Revenue is $15.2 million, with a median of $11.3 million in 2024.
- Per our database at Business Quant, Arcturus Therapeutics Holdings' Non-Current Deffered Revenue skyrocketed by 70924.89% in 2023 and then plummeted by 7034.07% in 2024.
- Arcturus Therapeutics Holdings' Non-Current Deffered Revenue (Quarter) stood at $19.9 million in 2021, then increased by 0.7% to $20.1 million in 2022, then surged by 111.73% to $42.5 million in 2023, then crashed by 70.34% to $12.6 million in 2024, then crashed by 66.52% to $4.2 million in 2025.
- Its Non-Current Deffered Revenue stands at $4.2 million for Q3 2025, versus $8.8 million for Q2 2025 and $9.6 million for Q1 2025.